Blog
From rare to common: The time to tackle rare diseases is now
As a paediatrician working in drug development, mother of a child with a rare disease, and founder of a medical research charity, Dr Harriet Holme understands the complexities of the rare disease landscape. Here, she argues that while balancing the interests of various stakeholders is essential, we cannot afford to delay action in the rare disease space any longer.
>200 companies
We have advised, worked with and supported dozens of funds and biotechs.
>500 million plus
Our input is benefitting patient populations worldwide.
>25 billion USD
Our repeat and long-term clients have realised significant value gains since we became involved in their programmes.